超声刺激胰腺β细胞释放胰岛素作为2型糖尿病潜在新疗法
本研究在大鼠INS 832/13 β细胞上探索非聚焦超声(峰值强度1 W/cm²,5分钟,频率400 kHz、600 kHz、800 kHz和1 MHz)促进胰岛素释放的效果。400和600 kHz时胰岛素释放约150 ng/10⁶细胞(p < 0.05)但伴随细胞活力显著丧失;800 kHz时释放24 ng/10⁶细胞(p < 0.05)且保留细胞活力,与促泌剂葡萄糖所致释放相当。作者认为超声有潜力成为纠正2型糖尿病患者分泌缺陷的新替代方法。
要点
- 800 kHz非聚焦超声(1 W/cm²,5分钟)使大鼠β细胞释放24 ng/10⁶细胞胰岛素且保留细胞活力。
- 400和600 kHz时释放约150 ng/10⁶细胞但伴随细胞活力显著丧失。
- 800 kHz所致胰岛素释放与促泌剂葡萄糖的报道值相当,处于细胞生理分泌能力范围内。
核心结论
- 非聚焦超声在800 kHz、峰值强度1 W/cm²、5分钟条件下可促进大鼠INS 832/13 β细胞释放胰岛素并保留细胞活力,作者认为超声有潜力成为纠正2型糖尿病患者分泌缺陷的新替代方法。
研究设计与样本
- 体外细胞实验,使用大鼠INS 832/13 β细胞,暴露于非聚焦超声5分钟、峰值强度1 W/cm²,频率为400 kHz、600 kHz、800 kHz和1 MHz;以酶联免疫吸附试验测定胰岛素释放,以台盼蓝拒染试验评估细胞活力。
诊断标准与关键数值
- 400和600 kHz超声暴露后胰岛素释放约150 ng/10⁶细胞(p < 0.05),但伴随细胞活力显著丧失。
- 800 kHz超声暴露后胰岛素释放24 ng/10⁶细胞(p < 0.05),且保留细胞活力。
- 800 kHz所致胰岛素释放与促泌剂葡萄糖的报道值相当。
局限性
- 研究为大鼠INS 832/13 β细胞的体外实验,作者结论为超声有潜力成为新替代方法,尚未在人体验证。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
Type 2 diabetes mellitus is a complex metabolic disease that has reached epidemic proportions in the United States and around the world. This disease is characterized by loss of insulin secretion and, eventually, destruction of insulin-producing pancreatic beta cells. Controlling type 2 diabetes is often difficult as pharmacological management routinely requires complex therapy with multiple medications, and loses its effectiveness over time. The objective of this study was to explore the effectiveness of a novel, non-pharmacological approach that uses the application of ultrasound energy to augment insulin release from rat INS 832/13 beta cells. The cells were exposed to unfocused ultrasound for 5 min at a peak intensity of 1 W/cm2 and frequencies of 400 kHz, 600 kHz, 800 kHz and 1 MHz. Insulin release was measured with enzyme-linked immunosorbent assay and cell viability was assessed via the trypan blue dye exclusion test. A marked release (approximately 150 ng/106 cells, p < 0.05) of insulin was observed when beta cells were exposed to ultrasound at 400 and 600 kHz as compared with their initial control values; however, this release was accompanied by a substantial loss in cell viability. Ultrasound application at frequencies of 800 kHz resulted in 24 ng/106 cells released insulin (p < 0.05) as compared with its unstimulated base level, while retaining cell viability. Insulin release from beta cells caused by application of 800-kHz ultrasound was comparable to that reported by the secretagogue glucose, thus operating within physiological secretory capacity of these cells. Ultrasound has potential as a novel and alternative method to current approaches aimed at correcting secretory deficiencies in patients with type 2 diabetes.
引用
- Suarez Castellanos I, Jeremic A, Cohen J, et al. Ultrasound Stimulation of Insulin Release from Pancreatic Beta Cells as a Potential Novel Treatment for Type 2 Diabetes. Ultrasound Med Biol. 2017. PMID: 28347531. doi:10.1016/j.ultrasmedbio.2017.01.007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。